Standard Biotools Inc ( (LAB) ) has released its Q2 earnings. Here is a breakdown of the information Standard Biotools Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Standard BioTools Inc., a prominent player in the biomedical research sector, specializes in providing advanced technologies for scientific discoveries, focusing on areas such as oncology and immunotherapy. The company reported its financial results for the second quarter of 2025, highlighting a strategic sale and financial performance.
In the second quarter of 2025, Standard BioTools reported a total revenue of $42 million, with $21.8 million from continuing operations. A significant highlight was the announced sale of SomaLogic to Illumina for up to $425 million, expected to close in the first half of 2026. The company anticipates having at least $550 million in cash and equivalents post-transaction, aiming to fuel its inorganic growth strategy.
Key financial metrics revealed a slight decline in revenue compared to the previous year, with a 3% drop in the second quarter and a 5% decrease for the first half of 2025. However, gross margins improved to 48.8% in Q2 2025 from 46.1% in Q2 2024, driven by product mix and operational efficiencies. Operating expenses were reduced by 11% year-over-year, reflecting merger cost synergies and productivity gains.
Despite a net loss of $17.7 million in Q2 2025, the company showed improvement from the previous year’s loss of $25.4 million. The adjusted EBITDA loss also improved by 7% year-over-year. Looking ahead, Standard BioTools expects combined revenue for 2025 to range between $165 million and $175 million, with continuing operations contributing $78 million to $83 million.
Standard BioTools is poised to leverage its strong balance sheet and streamlined operations to pursue strategic acquisitions and drive long-term shareholder value, with a target of achieving adjusted EBITDA break-even by 2026.